IR BioSciences Holdings
Michael K. Wilhelm
President, CEO, Director
This interview has expired.
Click here to find stocks, with exciting stories, and management committed to maximizing shareholder value.
Special deals for our readers
Are you qualified for the Visa Black Card?
The World’s Most Prestigious and Versatile Credit Card. Apply Now!
Be a more profitable investor:
What’s Jim Cramer trading in his personal portfolio? Click here
Why are you still paying too much with Schwab, and and E-trade?? Step up to the #1 discount broker: TradeKing.
Find out why TradeKing.com was ranked #1 Discount Broker by SmartMoney Magazine two years running! (August 2006 & 2007).
LifeLock is the only Identity Theft Prevention Solution backed by a one-million dollar guarantee!Click here to get a 10% discount.
Click here to get access to powerful investing tools only available at Investor’s Business Daily.
IR BioSciences Holdings, Inc. is a development stage biotechnology company. Through its wholly owned subsidiary, ImmuneRegen BioSciences, Inc., the Company is engaged in the research and development of drug candidates, Homspera and its derivatives, Radilex and Viprovex. As of December 31, 2007, the Company had submitted preliminary study data to the United States Food and Drug Administration (FDA) and has been issued two Pre-Investigational New Drug (PIND) numbers, one for the use of Radilex in the treatment of acute radiation syndrome and the other for the use of Viprovex in the treatment of avian influenza.